高风险门诊ERCP后30天住院率:基于支架对比吲哚美辛试验数据集的二次分析发病率与危险因素分析
本研究基于支架对比吲哚美辛试验数据集的二次分析,纳入768例接受门诊ERCP且存在ERCP后胰腺炎高风险并离院回家的患者,21.9%在30天内需住院。与ERCP后立即住院者相比,离院后延迟住院者的ERCP后胰腺炎发生率(40.5% vs 30.9%,P=0.04)、中重度ERCP后胰腺炎发生率(24.4% vs 13.8%,P<0.01)及住院时间(6.2天 vs 3.7天,P<0.001)均更高。与30天住院相关的因素包括患者年龄(OR 0.98,95%CI 0.97-0.99)、胆道支架置入(OR 1.62,95%CI 1.05-2.48)和尝试胰管插管(OR 1.64,95%CI 1.02-2.64)。
要点
- 高风险门诊ERCP离院患者30天内住院率为21.9%。
- 延迟住院者ERCP后胰腺炎发生率40.5% vs 立即住院者30.9%(P=0.04)。
- 延迟住院者中重度胰腺炎24.4% vs 13.8%(P<0.01),住院时间6.2天 vs 3.7天(P<0.001)。
核心结论
- 高风险门诊ERCP离院患者30天内住院风险较高,且胰腺炎发生率更高、住院时间更长,部分因素可能预测该结局。
- 作者认为这些发现应影响高风险ERCP的决策与知情同意,并指出本队列中Oddi括约肌功能障碍患者比例过高可能限制向典型ERCP实践的推广。
研究设计与样本
- 基于支架对比吲哚美辛试验数据集的二次分析,纳入接受门诊ERCP且存在ERCP后胰腺炎高风险并离院回家的768例患者。
- 主要结局为门诊ERCP后30天内住院;采用单变量分析后多变量分析探索相关患者与操作因素,并控制潜在已知混杂因素。
主要发现
- 768例高风险门诊ERCP离院患者中21.9%在30天内需住院。
- 与ERCP后立即住院者相比,离院后延迟住院者的ERCP后胰腺炎发生率40.5% vs 30.9%(P=0.04)。
- 延迟住院者中重度ERCP后胰腺炎发生率24.4% vs 13.8%(P<0.01),住院时间6.2天 vs 3.7天(P<0.001)。
- 与30天住院相关的因素包括患者年龄(OR 0.98,95%CI 0.97-0.99)、胆道支架置入(OR 1.62,95%CI 1.05-2.48)和尝试胰管插管(OR 1.64,95%CI 1.02-2.64)。
关键数值与推荐
- 30天住院率21.9%(768例高风险门诊ERCP离院患者)。
- ERCP后胰腺炎发生率:延迟住院者40.5% vs 立即住院者30.9%(P=0.04)。
- 中重度ERCP后胰腺炎发生率:延迟住院者24.4% vs 立即住院者13.8%(P<0.01)。
- 住院时间:延迟住院者6.2天 vs 立即住院者3.7天(P<0.001)。
- 30天住院相关因素:年龄OR 0.98(95%CI 0.97-0.99)、胆道支架置入OR 1.62(95%CI 1.05-2.48)、尝试胰管插管OR 1.64(95%CI 1.02-2.64)。
临床怎么用
- 作者认为这些发现应影响高风险ERCP的决策与知情同意。
- 作者指出本队列中Oddi括约肌功能障碍患者比例过高可能限制向典型ERCP实践的推广。
局限性
- 本队列中Oddi括约肌功能障碍患者比例过高,可能限制向典型ERCP实践的推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: ERCP carries potential for serious adverse events, and there is risk for unplanned health encounters after the procedure. The primary objective of this study was to identify the rate of 30-day hospital admission after outpatient ERCP in patients at elevated risk for post-ERCP pancreatitis based on patient- and procedure-related risk factors. We also explored whether pancreatitis rates and lengths of hospital stay differ with delayed hospitalization (versus admission immediately after ERCP) and identified factors associated with 30-day hospital admission. METHODS: High-risk patients in the Stent Versus Indomethacin trial who underwent outpatient ERCP were identified. The primary outcome was hospital admission within 30 days after outpatient ERCP. Patient and procedural factors associated with 30-day hospital admission were explored by means of univariable analysis followed by multivariable analysis, controlling for potential known confounders. RESULTS: Among 768 patients at high risk for post-ERCP pancreatitis who underwent outpatient ERCP and were discharged home, 21.9% required hospitalization within 30 days. Compared with patients who underwent outpatient ERCP but were admitted immediately to the hospital after the procedure, patients who were discharged after ERCP and admitted later had a higher incidence of post-ERCP pancreatitis (40.5% vs 30.9%; P = .04), moderate to severe post-ERCP pancreatitis (24.4% vs 13.8%; P < .01), and longer length of hospital stay (6.2 d vs 3.7 d; P < .001). Factors associated with 30-day hospitalization included patient age (odds ratio [OR], 0.98; 95% CI, 0.97-0.99), biliary stent placement (OR, 1.62; 95% CI, 1.05-2.48), and attempt at pancreatic duct cannulation (OR, 1.64; 95% CI, 1.02-2.64). CONCLUSIONS: High-risk patients who undergo outpatient ERCP and are discharged home are at considerable risk for hospital admission within 30 days and have an increased rate of pancreatitis and longer length of hospital stay compared with outpatients admitted to the hospital immediately after ERCP, and some factors may predict this outcome. These findings should influence decision making and informed consent when electing to proceed with high-risk ERCP, recognizing that patients with sphincter of Oddi dysfunction were over-represented in this cohort, which may limit generalizability to a typical ERCP practice.
引用
- Yachimski P, Zhang J, Coté GA, et al. Thirty-day hospital admission following high-risk outpatient ERCP: incidence and analysis of risk factors based on a secondary analysis of the Stent Versus Indomethacin trial dataset. Gastrointest Endosc. 2025. PMID: 39914634. doi:10.1016/j.gie.2025.01.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。